Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
Authors:
Open Access
- 11 March 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-6
Abstract
Antibodies have been widely used for cancer therapy owing to their ability to distinguish cancer cells by recognizing cancer-specific antigens. Epidermal growth factor receptor (EGFR) is a promising target for the cancer therapeutics, against which several antibody clones have been developed and brought into therapeutic use. Another antibody clone, 528, is an antagonistic anti-EGFR antibody, which has been the focus of our antibody engineering studies to develop cancer drugs. In this study, we explored the interaction of 528 with the extracellular region of EGFR (sEGFR) via binding analyses and structural studies. Dot blotting experiments with heat treated sEGFR and surface plasmon resonance binding experiments revealed that 528 recognizes the tertiary structure of sEGFR and exhibits competitive binding to sEGFR with EGF and cetuximab. Single particle analysis of the sEGFR–528 Fab complex via electron microscopy clearly showed the binding of 528 to domain III of sEGFR, the domain to which EGF and cetuximab bind, explaining its antagonistic activity. Comparison between the two-dimensional class average and the cetuximab/sEGFR crystal structure revealed that 528 binds to a site that is shifted from, rather than identical to, the cetuximab epitope, and may exclude known drug-resistant EGFR mutations.Keywords
Funding Information
- Japan Society for the Promotion of Science (19H03511)
- Takahashi Industrial and Economic Research Foundation
- Hokuto Foundation for Bioscience
- YU-COE, Yamagata university
- Basis for Supporting Innovative Drug Discovery and Life Science Research (JP20am0101082)
This publication has 27 references indexed in Scilit:
- Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitationsChinese Journal of Cancer, 2011
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapyClinical and Experimental Immunology, 2009
- Structure-Based View of Epidermal Growth Factor Receptor RegulationAnnual Review of Biophysics, 2008
- Humanization of the Bispecific Epidermal Growth Factor Receptor × CD3 Diabody and Its Efficacy as a Potential Clinical ReagentClinical Cancer Research, 2006
- Automated electron microscope tomography using robust prediction of specimen movementsJournal of Structural Biology, 2005
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- Active and inactive conformations of the epidermal growth factor receptorBiochemical Society Transactions, 2004
- EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain DimerizationMolecular Cell, 2003
- Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular DomainsCell, 2002
- The EGFR family and its ligands in human cancerEuropean Journal of Cancer, 2001